Nektar Therapeutics Shares Surge 20% on Trial Data

Nektar Therapeutics shares jumped about 20% after reporting positive 52‑week Phase 2b data for rezpegaldesleukin in severe alopecia areata.
In the study, 29% (18 µg/kg) and 31% (24 µg/kg) of patients achieved SALT Score ≤20 from week 36 to week 52.
Overall week‑52 response rates were 25.8% (low dose) and 27.6% (high dose) versus 6.7% placebo (p=0.049).
The trial enrolled 92 patients, 94% completed the 16‑week extension, and safety remained favorable with twice‑monthly dosing.